October 20-21, 1999


Planning Clinical Development in Catheter Related Bacteremia, Ray Zhu, PhD, Biostatistics, Rhone-Poulenc Rorer

Isaam Raad, MD, Chief, Section of Infection Control, Professor of Medicine, MD Anderson Cancer Center, Houston, TX

LEVAQUIN® (levofloxacin), Tablets or Injection for PRSP and PISP in Community-Acquired Pneumonia, Edward Cox, M.D., Medical Officer/DSPIDP

LEVAQUINâ (levofloxacin) Graham Burton, MD, Global Clinical Research and Regulatory Affairs

Reporting Rates for Serious Cardiac Dysrhythmias Among Fluoroquinolones, Azithromycin, Clarithromycin, and Cefuroxime, Allen Brinker, MD, MS, Office of Postmarking Drug Risk Assessment (OPDRA)

Moxifloxacin, Clinical Efficacy, Andrea Meyerhoff MD MSc DTMH, Division of Special Pathogens, US FDA

A Review of the Safety of Moxifloxacin Hydrochloride, Leonard Sacks MD, Medical Officer/DSPIDP (HTM) (PPT)

NDA 21-085 Avelox (moxifloxacin hydrochloride tablets) Bayer Pharmaceutical Division, Bayer Corporation ppt html